



Irish Pharmaceutical
Healthcare Association



EUROPEAN ELECTION MANIFESTO

Dublin

1 BETTER HEALTH FOR
ALL EUROPEANS

2 CREATING JOBS
THAT MATTER

3 SUPPORTING
INNOVATION

4 ENCOURAGING
SUSTAINABILITY



OUR KEY ASKS

1. BETTER HEALTH FOR ALL EUROPEANS

The pharmaceutical industry is an essential partner in health care. In Ireland and Europe, we strive to advance standards of care and outcomes for patients through innovative medicines including vaccines. When Irish and European policies prioritise access to new medicines including vaccines, we help deliver outcomes that matter to patients - allowing people to live longer, healthier lives, addressing chronic illnesses and improving survival rates for many diseases.

While health remains a national competence, our industry stands ready to work closely with European health leaders to enable faster and fairer access to medicines for patients in Ireland and throughout the EU.

The proposed new pharmaceutical legislation which the Parliament is voting on in April will continue to be assessed in dialogues in the next parliamentary term. IPHA remains concerned that the overall impact of the legislation will make Europe less competitive and less attractive as a region for researching and developing medicines including vaccines. Any reductions of incentives for companies to discover, develop and deliver new treatments is not in the best interests of patients in Ireland and Europe. IPHA believes that the legislation will need focused attention from MEPs in the 2024-29 term to support innovation in medicines.



HOW TO IMPROVE PATIENT OUTCOMES:

- Enhance the capacity of the European Medicines Agency to assess medicines more quickly
- Support the EFPIA commitment to file for reimbursement in all Member States for all centrally- authorised medicines within two years of authorisation.
- As ENVI committee recommended, do not link Regulatory Data Protection (RDP) to continuous supply in all 27 Member States.
- Ensure a predictable and streamlined EU framework for joint clinical assessment process, supporting national HTA bodies and collaboration with industry.
- Support an EU Immunisation Strategy that strengthens protection against vaccine-preventable diseases across all generations.
- Prioritise and extend Europe's Beating Cancer Plan and incorporate a European Cardiovascular Health Check into national cardiovascular plans.

2. CREATING JOBS THAT MATTER

45,000 people directly work in the pharmaceutical industry in Ireland and 875,000 in Europe. Through their highly skilled work, they help deliver better healthcare outcomes for millions of people throughout the world. Ireland's development as a pharmaceutical hub is a European and global success story which should be built upon. In every part of Ireland, people are working on this vital European and global success. We need to continue to create more of these high-value jobs in the pharmaceutical sector not just in Ireland but across the EU, building upon the 875,000 jobs already in place. These jobs matter for millions of people around the world, day in, day out.



HOW TO SUSTAIN AND BUILD JOBS:

- Truly competitiveness-proof all new EU laws and regulations affecting pharmaceutical and life sciences sectors.
- Continue partnership investment with industry in research through EU framework programmes.
- Support open, rules-based trade and evidence-based policies at WTO and WHO, recognising the importance of intellectual property protection.

3. SUPPORTING INNOVATION

Ireland's heritage in biopharmaceutical innovation is key to attracting new investments which will spur new medicines research, development and manufacturing, not only here but throughout Europe. A strong EU pharmaceutical industry focusing on innovation is critical to support Europe's political ambitions to beat cancer, tackling its entire disease pathway; and to tackle other continued public health challenges such as anti-microbial resistance, Alzheimer's and dementia.



HOW TO ENCOURAGE AND SUPPORT INNOVATION:

- Strengthen and add to EU intellectual property rights for medicines innovation in the revision of pharmaceutical legislation.
- A commitment from all stakeholders to drive innovation and achieve meaningful progress towards addressing Unmet Medical Need.
- Facilitate and encourage more pan-European and cross-border cooperation and exchange of evidence based information between national health systems via the European Health Data Spaces (EHDS).
- Focus on Europe being prepared for the next pandemic and tripledemic in the short term.
- The European Commission should put in place a comprehensive health & life sciences strategy at the heart of the next mandate.

4. ENCOURAGING THE SUSTAINABILITY OF THE PHARMACEUTICAL INDUSTRY

Climate change is one of the greatest challenges of our time. The European Green Deal can create a more resilient, sustainable, and competitive economy that works for people and the planet. The pharmaceutical industry will play its part in achieving these goals and will evolve in the face of changing sustainable practices and environmental impact. Industry is committed to a balanced approach in addressing concerns around risks associated with pharmaceuticals in the environment. We believe that Environmental Risk Assessments (ERAs) are indispensable in assessing the potential environmental risk of pharmaceuticals, and the potential impact of human medicines and their manufacture on the environment. However, they can be effective without being linked to specific product marketing authorisations.



HOW TO SUPPORT SUSTAINABILITY EFFORTS:

- Ensure continued funding and advisory supports for the industry to further encourage sustainability initiatives across Ireland and Europe.
- Implement Environmental Risk Assessments at production level, rather than marketing authorisation per product, so as to avoid creating barriers to access for new treatments for patients.
- Implement realistic regulatory change pathways to maintain medicines production and supply resilience, avoiding sudden or impossible change in chemicals, such as Pfas, or other domains.

Critical Committees: MEPs will have a crucial role to play in advancing the key asks of the pharmaceutical industry in the next mandate of the European Parliament – particularly through the ENVI (Environment, Public Health and Food Safety) and ITRE (Industry, Research and Energy) parliamentary committees. IPHA respectfully requests that Ireland's MEPs formally join these committees to ensure maximum impact.



abbvie

Alimera

astellas

A.MENARINI
PHARMACEUTICALS IRELAND LTD
Healthcare for Life

AMGEN



Biogen

Boehringer
Ingelheim

Bristol Myers Squibb®



Daiichi-Sankyo

GILEAD

GRÜNENTHAL

GSK


HALEON

IPSEN
Innovation for patient care

Janssen

Jazz Pharmaceuticals

kenvue



Lilly

Lundbeck

Dublin

MERCK

MSD

mundipharma

NOVARTIS

novo nordisk®

Perrigo®

Pfizer

reckitt

Roche

sanofi

SERVIER*

Takeda

TILLOTTS PHARMA
ZERIA GROUP

ucb

IPHA members
employing
in the Dublin
Constituency



The impact of the biopharmaceutical industry in Ireland

The **Dublin** constituency is a European hub of innovation and manufacturing – bringing life-enhancing medicines and vaccines to patients throughout Europe and around the world.

ENCOURAGE THE SUSTAINABILITY OF THE PHARMACEUTICAL INDUSTRY:

Novo Nordisk Ireland launched TakeAction: 100 & Beyond 'Cycle to School' initiative, providing five DEIS primary schools with new cycling equipment to support physical wellbeing and environmental sustainability in local communities across Ireland.

SUPPORTING INNOVATION AND CREATING JOBS THAT MATTER:

Pfizer is investing €1.2 billion in their Grange Castle site, doubling its capacity for biological drug substance manufacturing at the facility and creating between 400-500 jobs.

SUPPORTING INNOVATION:

Gilead Sciences opened its first Global Pediatric Drug Development Centre outside of the US in Dublin. The Centre is responsible for coordinating paediatric clinical trials for seven products across 18 countries, with current trials investigating paediatric treatments for HIV, hepatitis B and COVID-19.



BETTER HEALTH FOR ALL EUROPEANS:

In February 2024, Takeda Products Ireland initiated and funded "I am Number 17" – a campaign, in partnership with Rare Ireland and Rare Disease Ireland, the aim of which was to promote better understanding and awareness of rare diseases in Ireland.

ENCOURAGE THE SUSTAINABILITY OF THE PHARMACEUTICAL INDUSTRY:

MSD Dublin Biotech work with VOICE, an environmental charity, that empowers individuals and local communities to take positive action to conserve our natural resources.

GIVING BACK TO THE COMMUNITY:

The Pfizer cycle has raised over €446,451 for the Irish Cancer Society and see's Pfizer colleagues take part in a 300km cycle from Pfizer Grange Castle to Pfizer Ringaskiddy.

GIVING BACK TO THE COMMUNITY:

Gilead are the largest private funder of non-profit HIV programmes in the world, supporting a number of organisations in Ireland which provide community testing for HIV, strive to end the stigma around HIV and work towards ending new HIV transmissions

ENCOURAGE THE SUSTAINABILITY OF THE PHARMACEUTICAL INDUSTRY:

Novartis' Elm Park Campus is 100% single plastics free and hopes to be fully carbon/water/plastic neutral by 2030. An estimated 5,000 trees have been saved on account of its usage of electronic signatures internally.

DEVELOPING STEM SKILLS:

Janssen proudly support the WiSTEM2D Programme which inspires and supports women to pursue a career in STEM after university. In 2023 it awarded 62 outstanding female students across five universities.

DEVELOPING STEM SKILLS:

IPHA member companies in the region help to nurture STEM skills among young people in primary and secondary schools through programmes like the Junior Achievement Ireland.

The biopharmaceutical industry in Ireland

The biopharmaceutical industry – both IPHA member companies and non-IPHA companies – is a major contributor to Ireland’s economic growth through 45,000 direct and many more indirect jobs, exports, corporation and payroll taxes, and local spending power from salaries. We are a steadfast partner for Ireland in keeping the economy resilient and in raising standards of care for patients in Ireland.



Research and Development



Manufacturing Process Development



Regulatory Affairs



Global Shared Services



Digital and Data Analytics




Supply Chain Management



Quality Activities



Clinical Trial Management (CRO)



Software Development



Sales and Marketing

SUBSTANTIAL PHARMACEUTICAL OPERATIONS TAKE PLACE IN IRELAND ON A DAILY BASIS IN THESE AREAS

45,000

Direct employees
in Ireland

875,000

Employees
in Europe

>€116

Billion in annual
exports

36.9/100

Highest rate of
STEM graduates
in the EU

A European
hub of RDI
with a pipeline
of skilled
talent

>90

biopharmaceutical
plants in Ireland

FROM IRELAND TO THE WORLD

BRINGING MEDICINES TO PATIENTS THAT NEED THEM

The medicines made here, impact patients not just in Ireland and Europe but around the globe. They include treatments for many types of **cancer, leukaemia, heart disease, rare diseases, stroke, neurological disorders, HIV, Hepatitis B and C, arthritis, MS, ulcerative colitis, psoriasis** among others. They also include **vaccines**.



**Irish Pharmaceutical
Healthcare Association**

**Irish Pharmaceutical
Healthcare Association**

7 Clanwilliam Terrace
Dublin 2, D02 CC64

Tel: +353 (0)1 661 0018

Email: info@ipha.ie

www.ipha.ie